Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurocrine Acknowledges Potential Need For More Indiplon Data

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm said its review of an “approvable” and a “not approvable” letter for different formulations of the insomnia agent suggest FDA may seek additional studies.

You may also be interested in...



Pfizer Drops Indiplon, Returns Rights To Neurocrine

Pfizer will continue to support the insomnia product for up to six months.

Pfizer Drops Indiplon, Returns Rights To Neurocrine

Pfizer will continue to support the insomnia product for up to six months.

FDA’s Mixed Response To Indiplon Is Pfizer/Neurocrine’s Rude Awakening

Neurocrine will meet with FDA within 10 days to discuss the “approvable” and “not approvable” letters for the insomnia product.

Topics

UsernamePublicRestriction

Register

PS064339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel